The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×

To the Editor: Capgras syndrome has been described in neurodegenerative diseases such as dementia with Lewy bodies as well as in psychiatric diseases. 1 Thus far, the atypical antipsychotics and decreased dosage of l -dopa have been utilized to treat Capgras syndrome in patients with Parkinson’s disease, and the outcomes have not been satisfactory. 2 , 3 Here we report a patient with Parkinson’s disease who showed Capgras delusions only during the “off” state. Increased doses of l -dopa resolved wearing-off and at the same time alleviated Capgras syndrome.

Case Report

Our patient was a 64-year-old housewife. At the age of 58, she developed a tremor in her left upper extremity that responded to a combination of l -dopa/carbidopa, 300 mg/day. At the age of 61, she showed difficulty in walking. Dopamine agonists pramipexole and pergolide relieved her symptoms. At the age of 63, she developed apathy, recent memory disturbance, and wearing off phenomenon. At the age of 64, she developed Capgras syndrome, and then she was admitted to our hospital. She showed an hour off state before each time she took l -dopa/carbidopa three times per day. In the off state, she was severely disabled (Hoehn and Yahr stage IV) and expressed anxiety such as restlessness, tension and hypersweating. She also developed the firm belief that an imposter replaced her husband. When the doctor asked her “Is this man your husband?” she answered “No, he is not my husband. He looks like my husband. My husband is walking outside. This man is posing as my husband and trying to steal my money.” In the “on” state, she was able to walk (Hoehn and Yahr stage III). Her conviction disappeared. She scored 20/30 on the Mini-Mental State Examination and 11/18 on the Frontal Assessment Battery. Verbal fluency was disturbed. Parkinsonism was typical for Parkinson’s disease such as asymmetric, predominantly resting tremor; limb rigidity; bradykinesia; and postural instability. She did not show frontal release signs, and other neurological examinations produced normal findings. A brain MRI revealed slight frontotemporal cortical atrophy, and SPECT imaging showed hypoperfusion in the posterior cingulated cortex, precuneus, and prefrontal cortex. Treatment with 5 mg donepezil did not improve her Capgras syndrome. Two weeks later, an increase in the l -dopa/carbidopa dosage to 500 mg/day was prescribed, and the wearing off phenomenon resolved. At the same time, the patient’s Capgras syndrome completely disappeared.

Comment

In our patient, symptoms of Capgras syndrome developed while she showed motor symptoms associated with dopamine deficiency. We increased the dosage of l -dopa and succeeded in alleviating the Capgras syndrome. Thus, we postulate that Capgras syndrome in our patient is not likely dopaminergic psychosis. It has been reported that loss of dopamine and subsequent dopamine replacement therapy lead to imbalances in many nondopaminergic transmitter systems. 4 Furthermore, Spiegel et al. 5 reported successful treatment with an antidepressant, a serotonin 2A receptor antagonist, to treat Capgras syndrome after a right anterior cerebral artery infarction. Taken together, the mechanism underlying Capgras syndrome might be associated with the balance of various neurotransmitter systems.

Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
Department of Neurology, Juntendo Tokyo Koto Geriatric Medical Center
Department of Neurology, Juntendo University School of Medicine
References

1. Josephs KA: Capgras syndrome and its relationship to neurodegenerative disease. Arch Neurol 2007; 64:1762–1766Google Scholar

2. Miwa H, Mizuno Y: Capgras syndrome in Parkinson’s disease. J Neurol 2001; 248:804–805Google Scholar

3. Roane DM, Rogers JD, Robinson JH, et al: Delusional misidentification in association with parkinsonism. J Neuropsychiatry Clin Neurosci 1998; 10:194–198Google Scholar

4. Nicholson SL, Brotchie JM: 5-Hydroxytryptamine (5-HT, serotonin) and Parkinson’s disease: opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur J Neurol 2002; 9(suppl 3):1–6Google Scholar

5. Spiegel DR, Laroia R, Samuels D: A possible case of Capgras syndrome after a right anterior cerebral artery cerebrovascular accident treated successfully with mirtazapine. J Neuropsychiatry Clin Neurosci 2008; 4:494Google Scholar